期刊文献+

碳酸镧在维生素D冲击治疗继发性甲状旁腺功能亢进的血液透析患者中的作用 被引量:1

下载PDF
导出
摘要 目的:观察碳酸镧在维生素D冲击治疗继发性甲状旁腺功能亢进的血透患者中的作用。方法:将43例继发性甲状旁腺功能亢进的血透患者随机分为各组:对照组、低剂量组、高剂量组,分别接受安慰剂、碳酸镧250 mg、碳酸镧500 mg口服治疗,每日3次。各组患者中,iPTH在300~500 pg/ml之间的口服阿法骨化醇软胶囊2μg,每周2次,在500-1000 pg/ml之间的为4μg,每周2次,根据iPTH的水平每2月调整一次。主要观察指标为血iPTH水平,次要观察指标为血磷、校正的血钙、钙-磷乘积水平和不良事件的发生率。结果:6个月治疗结束时,各组患者的iPTH分别为(289.1±36.9)pg/ml、(199.3±23.6)pg/ml、(181.5±25.9)pg/ml(289.1 vs.199.3,289.1 vs.181.5,均P<0.05),血磷水平分别为(6.5±1.3)mg/dl、(5.2±0.7)mg/dl、(5.4±0.7)mg/dl(6.5 vs.5.2,6.5 vs.5.4,均P<0.05),钙-磷乘积水平分别为(62.7±3.2)mg2/dl2、(49.9±1.9)mg2/dl2、(50.0±1.6)mg2/dl2(62.7 vs.49.9,62.7 vs.50.0,均P<0.05)。治疗结束时各组患者的校正血钙的差异无统计学意义。治疗过程中,高剂量组有一位患者出现严重便秘,一位患者明显食欲减退,不良事件发生率为6.67%。结论:在维生素D冲击治疗继发性甲状旁腺功能亢进的血透患者中使用碳酸镧可以预防高磷血症的发生、治疗高磷血症,确保冲击治疗的顺利进行。
出处 《中国中西医结合肾病杂志》 2015年第8期700-703,共4页 Chinese Journal of Integrated Traditional and Western Nephrology
  • 相关文献

参考文献22

  • 1National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis ,2003,42 (4 Suppl 3 ) : S1 - 201.
  • 2Moe SM, DrUeke T, Lameire N, et al. Chronic kidney disease - mineral - bone disorder: a new paradigm. Ad- Chronic Kidney Dis,2007,14 ( 1 ) :3 - 12.
  • 3Sun LY, Wang M, Yang L. Study of calcium - phosphorous me- tabolism and intact parathyroid hormone le-els in end stage renal disease patients. Beijing Da Xue Xue Bao, 2005,37 ( 2 ) : 147 - 150.
  • 4Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and mobidity in maintenance hemodialysis. J Am Soc Nephrol, 200d, 15 ( 8 ) :2208 - 2218.
  • 5Block GA, Port FK. Re - e-aluation of risks associated with hy- perphosphatemia and hyperparathyroidism in dialysis patients?: recommendations for a change in management. Am J Kidney Dis, 2000,35(6) :1226 - 1237.
  • 6Marco MP, Cra-er L, Betriu A, et al. Higher impact of mineral metabolism on cardio-ascular, mortality in a European hemodialy- sis population. Kidney Int Suppl,2003, ( 85 ) : S111 - S114.
  • 7Noordzij M, Kore-aar JC, Boeschoten EW, et al. Netherlands Co- operati-e Study on the Adequacy of Dialysis (NECOSAD) Study Group. The kidney disease outcomes quality initiati-e(K/DOQI) guidelines for bone metabolism and disease in CKD : association with mortality in dialysis patients. Am J Kidney Dis, 2005,46 (5) :925 -932.
  • 8Goodman WG. Medical management of secondary hyperparathy- roidism in chronic renal failure. Nephrol Dial Transplant, 2003, 18 (suppl 3) :2 -8.
  • 9侯晓艳.骨化三醇冲击治疗血透患者继发性甲旁亢的疗效观察[J].中国中西医结合肾病杂志,2014,15(1):52-54. 被引量:24
  • 10刘慢慢,陈德君.双膦酸盐治疗血液透析患者继发性甲状旁腺功能亢进研究进展[J].中国中西医结合肾病杂志,2014,15(6):552-554. 被引量:2

二级参考文献32

  • 1魏守亮,张凌,陆文进.比较血液透析患者在不同PTH状态下低钙透析液的疗效[J].中国血液净化,2005,4(10):531-534. 被引量:10
  • 2魏日胞,陈香美,蔡广研,王涌.尿毒症患者不同PTH浓度对阿法D_3冲击疗效的影响[J].军医进修学院学报,2006,27(5):349-351. 被引量:2
  • 3National Kidney Foundation. K/DOQI clinical practice guidelines for bne metabolism and disease in chronic kidney disease. Am J Kidney Dis,2003,42 (4 Suppl 3 ) : S1 - $201.
  • 4Eduardo S, Adriana D, Alex JB. Kidney International, 2002,61 ( suppl 80) :S143 - S148.
  • 5Jamaluddin E J, Gafor AHA, Yean LC, et al. Oral paricalcitol ver- sus oral calcitriol in continuous ambulatory peritoneal dialysis pa- tients with secondary hyperparathyroidism. Clinical and Experi- mental Nephrology,2013.1 -8.
  • 6Bhuriya R, Singh M, Molnar J, et al. Bisphosphonate use in women and the risk of atrial fibrillation:a systematic review and meta - analysis. International Journal of Cardiology, 2010, 142 (3) :213 - 17.
  • 7VanBeek E, Hoekstra M, Vande Ruit M, et al. Structural require- ments for bisphosphanates actions in vitro. J Bone Miner Res, 1994,9 : 1875.
  • 8Huang CY,Zheng CM, Wu CC, et al. Effects of Pamidronate and Calcitriol on the Set Point of the Parathyroid Gland in Postmeno- pausal Hemodialysis Patients with Secondary Hyperparathyroid- ism. Nephron Clinical Practice, 2013,122 ( 3 - 4) : 93 - 101.
  • 9Moe S, Drtieke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int.2006.69 ( 11 ) : 1945 - 1953.
  • 10Fraser WD. Hyperparathyroidism. The Lancet, 2009,374 (9684) : 145 - 158.

共引文献24

同被引文献3

引证文献1

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部